MarketBeat
18 Aug 2026, 06:04 UTC · 1h ago
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
18 Aug 2026, 06:04 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Tandem is shifting international markets from distributor arrangements to direct sales, which has resulted in at least a 30% increase in selling prices per market. — Direct sales significantly improve margins through higher pricing and better control over patient renewals and volume.
+0.60Tandem has filed for FDA clearance of a tubeless version of the Mobi pump, targeting a market segment where the company has not historically competed. — A tubeless offering expands the Total Addressable Market (TAM) and removes a major hardware barrier for new users.
+0.50The company is transitioning to a pharmacy distribution model in the U.S. to eliminate high upfront DME costs, with a goal of moving 80% of pumps through this channel in 2-3 years. — Reducing out-of-pocket barriers ($800-$1,000) is expected to accelerate adoption rates among insulin-dependent patients.
+0.40Continue reading
6 related stories
Search tags
Tandem plans to begin a pivotal trial later this year for a fully closed-loop algorithm designed for both type 1 and type 2 diabetes patients. — A fully closed-loop system increases product competitiveness and appeal to the underpenetrated type 2 market.
+0.30Management views GLP-1 medicines as complementary rather than competitive, noting that outcomes improve when used alongside automated insulin delivery. — This mitigates investor fears that GLP-1s will cannibalize the insulin pump market by positioning them as synergistic treatments.
+0.20Which stocks this story touches
The company is expanding market access via pharmacy distribution, launching a new tubeless pump, and increasing margins through international direct sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
2h ago
